In the Clinic
How Our New Particle Accelerator Will Make Cancer Imaging and Treatment More Precise
The launch of a 20-ton instrument and a facility for producing radioactive imaging molecules will allow our doctors and scientists to monitor cancers in unparalleled detail.
Novel Cancer-Targeting Investigational Nanoparticle Receives FDA IND Approval for First-In-Human Trial
Researchers at Memorial Sloan Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.